Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization

Journal of Controlled Release

Volumn 177, Issue 1, 2014, Pages 20-26

  Orr, Mark T ^a   Kramer, Ryan M ^a   Barnes, Lucien V ^a   Dowling, Quinton M ^a   Desbien, Anthony L ^a   Beebe, Elyse A ^a   Laurance, John D ^a   Fox, Christopher B ^a   Reed, Steven G ^a   Coler, Rhea N ^a   Vedvick, Thomas S ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

Adjuvant; Lyophilization; Nanoemulsion; Vaccine

Indexed keywords

ADJUVANT; ELEVATED TEMPERATURE; LONG TERM STABILITY; LYOPHILIZATION; MYCOBACTERIUM TUBERCULOSIS; NANOEMULSION; TECHNOLOGICAL BARRIERS; VACCINE ADJUVANTS;

ANTIGENS; CHAINS; VACCINES;

DISEASES;

BCG VACCINE; HYBRID PROTEIN; ID93 FUSION PROTEIN; SQUALENE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BCG VACCINATION; CONTROLLED STUDY; DRUG STABILITY; FEMALE; FREEZE DRYING; INFECTION PREVENTION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NANOEMULSION; NONHUMAN; PRIORITY JOURNAL; TEMPERATURE; TH1 CELL; THERMOSTABILITY; TUBERCULOSIS;

ADJUVANT; LYOPHILIZATION; NANOEMULSION; VACCINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; B-LYMPHOCYTES; BACTERIAL LOAD; EMULSIONS; FEMALE; FREEZE DRYING; LEUKOCYTE COUNT; LUNG; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; NANOSTRUCTURES; SPLEEN; T-LYMPHOCYTES; TEMPERATURE; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84892660948     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.12.025     Document Type: Article

References (30)

1. PATH Summary of Stability Data for Licensed Vaccines, in 2012 Working in Tandem Ltd Seattle, WA
2. D. Chen, and D. Zehrung Desirable attributes of vaccines for deployment in low-resource settings J. Pharm. Sci. 102 2013 29 33
3. J. Zhang, E. Pritchard, X. Hu, T. Valentin, B. Panilaitis, F.G. Omenetto, and D.L. Kaplan Stabilization of vaccines and antibiotics in silk and eliminating the cold chain Proc. Natl. Acad. Sci. 109 2012 11981 11986
4. W. Wang Lyophilization and development of solid protein pharmaceuticals Int. J. Pharm. 203 2000 1 60 (Pubitemid 30627625)
5. J.C. Kasper, G. Winter, and W. Friess Recent advances and further challenges in lyophilization Eur. J. Pharm. Biopharm. 85 2 Oct 2013 162 169
6. S.G. Reed, S. Bertholet, R.N. Coler, and M. Friede New horizons in adjuvants for vaccine development Trends Immunol. 30 2009 23 32
7. U.S. Food, and Drug Administration Vaccines and Related Biological Products Advisory Committee Meeting, in 2012
8. A.L. Clausi, S.A. Merkley, J.F. Carpenter, and T.W. Randolph Inhibition of aggregation of aluminum hydroxide adjuvant during freezing and drying J. Pharm. Sci. 97 2008 2049 2061
9. J. Rossi, and J.C. Leroux Principles in the development of intravenous lipid emulsions K.M. Wasan, Role of Lipid Excipients in Modifying Oral and Parenteral Drug Delivery: Basic Principles and Biological Examples 2007 John Wiley & Sons, Inc. Hoboken, NJ 88 123
10. WHO global tuberculosis control report 2010. Summary Cent Eur J Public Health 18 2010 237
11. A.M. Checkley, and H. McShane Tuberculosis vaccines: progress and challenges Trends Pharmacol. Sci. 32 2011 601 606
12. R. Rowland, and H. McShane Tuberculosis vaccines in clinical trials Expert. Rev. Vaccines 10 2011 645 658
13. P. Andersen, and T.M. Doherty The success and failure of BCG - implications for a novel tuberculosis vaccine Nat. Rev. Microbiol. 3 2005 656 662 (Pubitemid 41052152)
14. L.J. Abu-Raddad, L. Sabatelli, J.T. Achterberg, J.D. Sugimoto, I.M. Longini Jr., C. Dye, and M.E. Halloran Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics Proc. Natl. Acad. Sci. U. S. A. 106 2009 13980 13985
15. J.L. Flynn, and J. Chan Immunology of tuberculosis Annu. Rev. Immunol. 19 2001 93 129 (Pubitemid 32368031)
16. A.M. Cooper Cell-mediated immune responses in tuberculosis Annu. Rev. Immunol. 27 2009 393 422
17. S. Bertholet, G.C. Ireton, D.J. Ordway, H.P. Windish, S.O. Pine, M. Kahn, T. Phan, I.M. Orme, T.S. Vedvick, S.L. Baldwin, R.N. Coler, and S.G. Reed A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis Sci. Transl. Med. 2 2010 53ra74
18. S. Bertholet, G.C. Ireton, M. Kahn, J. Guderian, R. Mohamath, N. Stride, E.M. Laughlin, S.L. Baldwin, T.S. Vedvick, R.N. Coler, and S.G. Reed Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis J. Immunol. 181 2008 7948 7957
19. M.T. Orr, C.B. Fox, S.L. Baldwin, S.J. Sivananthan, E. Lucas, S. Lin, T. Phan, J.J. Moon, T.S. Vedvick, S.G. Reed, and R.N. Coler Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis J. Control. Release 172 2013 190 200
20. L.K. Ching, F. Mompoint, J.A. Guderian, A. Picone, I.M. Orme, R.N. Coler, S.G. Reed, and S.L. Baldwin Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay J. Immunol. Methods 373 2011 54 62
21. R.C. Anderson, C.B. Fox, T.S. Dutill, N. Shaverdian, T.L. Evers, G.R. Poshusta, J. Chesko, R.N. Coler, M. Friede, S.G. Reed, and T.S. Vedvick Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations Colloids Surf. B: Biointerfaces 75 2010 123 132
22. R.N. Coler, S. Bertholet, M. Moutaftsi, J.A. Guderian, H.P. Windish, S.L. Baldwin, E.M. Laughlin, M.S. Duthie, C.B. Fox, D. Carter, M. Friede, T.S. Vedvick, and S.G. Reed Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant PLoS One 6 2011 e16333
23. C.A. Schneider, W.S. Rasband, and K.W. Eliceiri NIH Image to ImageJ: 25 years of image analysis Nat. Methods 9 2012 671 675
24. C.B. Fox, R.C. Anderson, T.S. Dutill, Y. Goto, S.G. Reed, and T.S. Vedvick Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions Colloids Surf. B: Biointerfaces 65 2008 98 105
25. M.F. Bachmann, and G.T. Jennings Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns Nat. Rev. Immunol. 10 2010 787 796
26. L.R. Shiow, D.B. Rosen, N. Brdickova, Y. Xu, J. An, L.L. Lanier, J.G. Cyster, and M. Matloubian CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs Nature 440 2006 540 544
27. M.T. Orr, M.S. Duthie, H.P. Windish, E.A. Lucas, J.A. Guderian, T.E. Hudson, N. Shaverdian, J. O'Donnell, A.L. Desbien, S.G. Reed, and R.N. Coler MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant Eur. J. Immunol. 43 2013 2398 2408
28. M. Frentsch, O. Arbach, D. Kirchhoff, B. Moewes, M. Worm, M. Rothe, A. Scheffold, and A. Thiel Direct access to CD4 + T cells specific for defined antigens according to CD154 expression Nat. Med. 11 2005 1118 1124 (Pubitemid 41486836)
29. T.K.A. Thomas, J. Anchordoquy, Marion d.C. Molina, S. Dean Allison, M.M.P. Ye Zhang, Yvonne K. Lentz, and Gary S. Koe Lyophilization of biopharmaceuticals 2004 American Association of Pharmaceutical Scientists
30. B. Ivins, P. Fellows, L. Pitt, J. Estep, J. Farchaus, A. Friedlander, and P. Gibbs Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs Vaccine 13 1995 1779 1784 (Pubitemid 26013113)